24 pending office actions • 6 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Juno Therapeutics, Inc. | 19 |
| Fred Hutchinson Cancer Center | 1 |
| Celgene Corporation | 1 |
| Juno Therapeutics GmbH | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| The Johns Hopkins University | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19312145 | Untitled | Juno Therapeutics, Inc. | WEHBE, ANNE MARIE SABRINA | 1634 | Non-Final OA | |
| 19031042 | METHODS FOR THE TREATMENT OF B CELL MALIGNANCIES USING ADOPTIVE CELL THERAPY | Fred Hutchinson Cancer Center | HILL, KEVIN KAI | 1638 | Non-Final OA | Jan 17, 2025 |
| 18286981 | T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR STEM CELL TRANSPLANT | Celgene Corporation | LUNDE, GRACE HENRY | 1641 | Non-Final OA | Oct 13, 2023 |
| 18284725 | METHODS FOR DOSING AND TREATMENT WITH A COMBINATION OF A CHECKPOINT INHIBITOR THERAPY AND A CAR T CELL THERAPY | Juno Therapeutics, Inc. | CHHAY, BONIRATH | 1645 | Non-Final OA | Sep 28, 2023 |
| 18283434 | METHODS OF DETERMINING POTENCY OF A THERAPEUTIC CELL COMPOSITION | Juno Therapeutics, Inc. | GAO, ASHLEY HARTMAN | 1678 | Non-Final OA | Sep 21, 2023 |
| 18365950 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR GPRC5D AND BCMA | Juno Therapeutics, Inc. | DUNN, LINDSAY MICHELLE | 1644 | Non-Final OA | Aug 04, 2023 |
| 18019460 | ANTI-IDIOTYPIC ANTIBODIES TO ROR1-TARGETED BINDING DOMAINS AND RELATED COMPOSITIONS AND METHODS | Juno Therapeutics, Inc. | SUNSHINE, HANNAH LOUISE | 1647 | Non-Final OA | Feb 02, 2023 |
| 18011780 | ENGINEERED T CELLS CONDITIONALLY EXPRESSING A RECOMBINANT RECEPTOR, RELATED POLYNUCLEOTIDES AND METHODS | Juno Therapeutics GmbH | ZHU, JIANJIAN | 1631 | Non-Final OA | Dec 20, 2022 |
| 17921614 | COMBINATION OF BCMA-DIRECTED T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | Juno Therapeutics, Inc. | JOHNSON, CHRISTOPHER LINDSAY | 1691 | Final Rejection | Oct 26, 2022 |
| 17921291 | STABILIZATION OF POLYETHYLENEIMINE-DEOXYRIBONUCLEIC ACID COMPLEX SIZE AND ACTIVITY | Juno Therapeutics, Inc. | BURKHART, MICHAEL D | 1638 | Non-Final OA | Oct 25, 2022 |
| 17917923 | METHODS AND USES RELATED TO CELL THERAPY ENGINEERED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING B-CELL MATURATION ANTIGEN | Juno Therapeutics, Inc. | STOICA, ELLY GERALD | 1647 | Non-Final OA | Oct 07, 2022 |
| 17799239 | BCMA-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND METHODS AND USES THEREOF | Juno Therapeutics, Inc. | GRABER, JAMES J | 1631 | Non-Final OA | Aug 11, 2022 |
| 17794245 | METHODS FOR DOSING AND TREATMENT OF FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA IN ADOPTIVE CELL THERAPY | Juno Therapeutics, Inc. | FORD, VANESSA L | 1674 | Final Rejection | Jul 20, 2022 |
| 17850875 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | Juno Therapeutics, Inc. | WEHBE, ANNE MARIE SABRINA | 1634 | Final Rejection | Jun 27, 2022 |
| 17782584 | METHODS RELATED TO TOXICITY AND RESPONSE ASSOCIATED WITH CELL THERAPY FOR TREATING B CELL MALIGNANCIES | Juno Therapeutics, Inc. | REDDIG, PETER J | 1646 | Non-Final OA | Jun 03, 2022 |
| 17774821 | COMBINATION OF A T CELL THERAPY AND (S)-3-[4-(4-MORPHOLIN-4-YLMETHYL-BENZYLOXY)-L-OXO-L,3-DIHYDRO-ISOINDOL-2-YL]-PIPERIDINE-2,6-DIONE | Juno Therapeutics, Inc. | BUTTICE, AUDREY L | 1647 | Non-Final OA | May 05, 2022 |
| 17774464 | METHODS OF DETERMINING ATTRIBUTES OF THERAPEUTIC T CELL COMPOSITIONS | Juno Therapeutics, Inc. | BAILEY, STEVEN WILLIAM | 1687 | Non-Final OA | May 04, 2022 |
| 17297771 | METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | Juno Therapeutics, Inc. | LU, CHENG | 1642 | Non-Final OA | May 27, 2021 |
| 17291536 | PROCESS FOR PRODUCING GENETICALLY ENGINEERED T CELLS | Juno Therapeutics, Inc. | VAN BUREN, LAUREN K | 1638 | Non-Final OA | May 05, 2021 |
| 17290060 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D) | Memorial Sloan Kettering Cancer Center | BENAVIDES, JENNIFER ANN | 1675 | Final Rejection | Apr 29, 2021 |
| 17266995 | METHODS FOR ASSESSING INTEGRATED NUCLEIC ACIDS | Juno Therapeutics, Inc. | ZAHORIK, AMANDA MARY | 1636 | Non-Final OA | Feb 08, 2021 |
| 16634497 | REAGENTS FOR EXPANDING CELLS EXPRESSING RECOMBINANT RECEPTORS | Juno Therapeutics, Inc. | KIM, YUNSOO | 1641 | Non-Final OA | Jan 27, 2020 |
| 16609733 | COMBINATION OF A CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | Juno Therapeutics, Inc. | BURKHART, MICHAEL D | 1638 | Final Rejection | Oct 30, 2019 |
| 16500352 | ENGINEERED CELLS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) OR A MODIFIED FORM THEREOF AND RELATED METHODS | The Johns Hopkins University | STAVROU, CONSTANTINA E | 1632 | Final Rejection | Oct 02, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial